TG Therapeutics Inc (1TGTX)

Currency in EUR
23.21
-0.23(-0.98%)
Closed·
1TGTX Scorecard
Full Analysis
Net income is expected to grow this year
1TGTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.2123.21
52 wk Range
23.2039.99
Key Statistics
Prev. Close
23.21
Open
23.21
Day's Range
23.21-23.21
52 wk Range
23.2-39.99
Volume
-
Average Volume (3m)
40
1-Year Change
-
Book Value / Share
1.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1TGTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

TG Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral

TG Therapeutics Inc Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Industry
-
Sector
-
Market
Italy

Compare 1TGTX to Peers and Sector

Metrics to compare
1TGTX
Peers
Sector
Relationship
P/E Ratio
63.7x−4.5x−0.5x
PEG Ratio
−1.48−0.050.00
Price/Book
13.9x2.6x2.6x
Price / LTM Sales
8.5x9.5x3.3x
Upside (Analyst Target)
-268.7%42.9%
Fair Value Upside
Unlock11.4%6.2%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

1TGTX Income Statement

People Also Watch

58.98
BMNR
+14.68%
465.58
APP
+2.11%
71.86
OKLO
-4.59%
161.17
CRCL
+1.35%
17.370
QBTS
+2.78%

FAQ

What Stock Exchange Does TG Therapeutics Inc Trade On?

TG Therapeutics Inc is listed and trades on the Milan Stock Exchange stock exchange.

What Is the Stock Symbol for TG Therapeutics Inc?

The stock symbol for TG Therapeutics Inc is "1TGTX."

What Is the TG Therapeutics Inc Market Cap?

As of today, TG Therapeutics Inc market cap is 3.31B.

What Is TG Therapeutics Inc's Earnings Per Share (TTM)?

The TG Therapeutics Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 1TGTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has TG Therapeutics Inc Stock Split?

TG Therapeutics Inc has split 0 times.

What is the current trading status of TG Therapeutics Inc (1TGTX)?

As of 12 Aug 2025, TG Therapeutics Inc (1TGTX) is trading at a price of 23.21, with a previous close of 23.21. The stock has fluctuated within a day range of 23.21 to 23.21, while its 52-week range spans from 23.20 to 39.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.